Global KSK7653 Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global KSK7653 market size was valued at US$ 29.33 million in 2025 and is forecast to a readjusted size of US$ 321 million by 2032 with a CAGR of 24.1% during review period.
In 2025, global HSK7653 production reached approximately 180,000 units.HSK7653, with the generic name Cofogliptin, is a new type of dipeptidyl peptidase 4 (DPP-4) inhibitor antidiabetic drug independently developed by a domestic enterprise with independent intellectual property rights. By specifically inhibiting the activity of DPP-4 enzyme, this drug prolongs the action time of endogenous incretins in the body, thereby promoting insulin secretion, inhibiting glucagon release, achieving stable regulation of blood glucose, and is not prone to causing adverse reactions such as hypoglycemia. As an oral antidiabetic drug, HSK7653 features convenient administration and good tolerability. It is mainly used for the treatment of type 2 diabetes, which can effectively improve the blood glucose control level of patients, provide a safe and efficient treatment option for patients with type 2 diabetes, and at the same time promote the independent innovation and development of the domestic antidiabetic drug field.
HSK7653 (generic name: Cofogliptin), as the world's first ultra-long-acting dipeptidyl peptidase 4 (DPP-4) inhibitor, occupies a differentiated competitive position in the field of type 2 diabetes treatment by virtue of its unique advantage of biweekly oral administration, showing significant market development potential. As an innovative drug independently developed by a domestic enterprise, this drug has complete independent intellectual property rights, breaking the long-term monopoly of imported DPP-4 inhibitors in the market and conforming to the development trend of independent innovation in the domestic antidiabetic drug field. Its mechanism of action has the characteristics of glucose-dependent "intelligent hypoglycemia", with good safety and tolerability, no obvious risk of hypoglycemia and neutral impact on body weight. It is suitable for special patient groups such as the elderly and those with renal insufficiency, with a wide range of clinical application scenarios and continuously improving recognition. At present, the global DPP-4 inhibitor market is in a stage of steady development, with both competition between imported original drugs and domestic generic drugs, as well as differentiated breakthroughs of new ultra-long-acting preparations. Relying on its core advantage of ultra-long-acting administration, HSK7653 is different from traditional daily and weekly preparations, effectively improving patient medication adherence and forming unique market competitiveness. With the advancement of medical insurance access, further exploration of clinical indications and expansion of combination therapy regimens, the market penetration of this drug will continue to strengthen. At the same time, relying on the cost and channel advantages of domestic innovative drugs, it will gradually expand its market coverage, which is expected to seize more market share in the fierce market competition, help reshape the pattern of the domestic DPP-4 inhibitor market, provide a more convenient and safe treatment option for patients with type 2 diabetes, and promote the diversified development of the domestic antidiabetic drug market.
This report is a detailed and comprehensive analysis for global KSK7653 market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global KSK7653 market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global KSK7653 market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global KSK7653 market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global KSK7653 market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for KSK7653
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global KSK7653 market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Haisco Pharmaceutical Group, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
KSK7653 market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
15 Mg / Tablet
30 Mg / Tablet
Market segment by Combination Therapy
HSK7653 + Metformin Combination
HSK7653 + Sitagliptin Combination
Market segment by Sales Channel
Hospital
Retail
Online
Market segment by Application
Type 2 Diabetes Mellitus
Insulin Resistance
Metabolic Syndrome
Others
Major players covered
Haisco Pharmaceutical Group
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe KSK7653 product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of KSK7653, with price, sales quantity, revenue, and global market share of KSK7653 from 2021 to 2026.
Chapter 3, the KSK7653 competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the KSK7653 breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and KSK7653 market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of KSK7653.
Chapter 14 and 15, to describe KSK7653 sales channel, distributors, customers, research findings and conclusion.